EUVIMEDEUVIMED entdecken
Crossref

Biologically Refined Oncological Resectability for Hepatocellular Carcinoma

Kenta Aso iD, Yoshinori Takeda iD, Atsushi Takahashi, Shoichi Irie, Yoshihiro Hirata, Hirofumi Ichida, Ryuji Yoshioka, Yoshihito Kotera, Yoshihiro Mise, Akio Saiura

Journal of Hepato-Biliary-Pancreatic Sciences · 2026

DOI: 10.1002/jhbp.70119 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Hepato-Biliary-Pancreatic Sciences, 2026. Verfasst von Kenta Aso und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary-Pancreatic Surgery, Juntendo University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Hepatectomy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Purpose Oncological resectability criteria for hepatocellular carcinoma (HCC) have been proposed to guide multidisciplinary treatment, but their validation remains limited. Incorporating biological factors may improve prognostic stratification and identification of borderline‐resectable HCC.

Methods

Patients undergoing initial hepatectomy for HCC (2009–2022) were classified as resectable (R), borderline‐resectable (BR)1, or BR2. Stratification of overall survival (OS) and recurrence‐free survival (RFS) was compared with the BCLC staging system. R‐group patients with alpha‐fetoprotein (AFP) ≥ 400 ng/mL and des‐gamma‐carboxy prothrombin (DCP) ≥ 400 mAU/mL were subclassified as biological‐BR.

Results

Among 391 patients (R: 330; BR1: 23; BR2: 38), survival stratification was comparable to the BCLC classification. Twenty‐six R‐group patients were reclassified as biological‐BR, with higher microvascular invasion rates (42.3%) and 5 year OS and 3 year RFS similar to BR1 patients (54.9% vs. 51.3%, p = 0.457; 38.1% vs. 25.0%, p = 0.954). Combining Biological BR with BR1 significantly improved time‐dependent prediction of 6 month recurrence, with an area under the receiver operating characteristic curve (Refined: 0.803; Original: 0.658, p ≤ 0.001, BCLC: 0.608, p ≤ 0.001) and net reclassification improvement (0.220 vs. Original; 0.446 vs. BCLC).

Conclusions

Refinement using AFP and DCP identified a biologically aggressive subset within the R group and may improve early recurrence prediction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHepatectomyHumansFemaleMaleNeoplasm StagingPrognosisalpha-FetoproteinsAgedMiddle AgedBiomarkers, TumorProtein PrecursorsRetrospective StudiesProthrombinSurvival RateBiomarkers

Stichwörter der Autor:innen

borderline resectablehepatocellular carcinomaoncological criteriaresectabilitytumor markers

Substanzen

alpha-FetoproteinsacarboxyprothrombinBiomarkers, TumorProtein PrecursorsProthrombinBiomarkers

Autor:innen und Institutionen

  • Department of Hepatobiliary-Pancreatic Surgery, Juntendo University School of Medicine, Tokyo, Japan.

ORCID-Profile: Kenta Aso, Yoshinori Takeda

Zitieren

APA

Aso, K., Takeda, Y., Takahashi, A., Irie, S., Hirata, Y., Ichida, H., Yoshioka, R., Kotera, Y., Mise, Y., & Saiura, A. (2026). Biologically Refined Oncological Resectability for Hepatocellular Carcinoma. Journal of Hepato-Biliary-Pancreatic Sciences. https://doi.org/10.1002/jhbp.70119

Vancouver

Aso K, Takeda Y, Takahashi A, Irie S, Hirata Y, Ichida H, et al. Biologically Refined Oncological Resectability for Hepatocellular Carcinoma. Journal of Hepato-Biliary-Pancreatic Sciences. 2026. doi:10.1002/jhbp.70119

BibTeX
@article{Aso2026,
  author = {Aso, Kenta and Takeda, Yoshinori and Takahashi, Atsushi and Irie, Shoichi and Hirata, Yoshihiro and Ichida, Hirofumi and Yoshioka, Ryuji and Kotera, Yoshihito and Mise, Yoshihiro and Saiura, Akio},
  title = {Biologically Refined Oncological Resectability for Hepatocellular Carcinoma},
  journal = {Journal of Hepato-Biliary-Pancreatic Sciences},
  year = {2026},
  doi = {10.1002/jhbp.70119}
}
Kostenlos starten →